A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and Significant Coronary Artery D
The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared with placebo (inactive medication), in reducing the risk of death, heart attack or stroke in participants with heart failure and significant coronary artery disease following an episode of decompensated heart failure.
Study phase: III
Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.
-Must have had an episode of worsening heart failure
-Must have evidence of significant coronary artery disease
-Must be medically stable
Primary disease category: Heart/Cardiovascular
Sponsor: Janssen Research and Development
Protocol number: RIVAROXHFA3001
Projected enrollment dates: April 2015 to April 2017
Official study title: A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure
External link(s):
Sarver Heart Center
ClinicalTrials.gov page:
http://www.clinicaltrials.gov/show/NCT01877915